---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-010323"
form_type: "8-K"
ticker: "CTXR"
cik: "0001506251"
company_name: "Citius Pharmaceuticals, Inc."
filed_at: "2023-02-10T23:59:59+00:00"
generated_at: "2026-06-19T17:55:56.225648+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Citius Pharma reports Q1 net loss of $3.6M ($0.02/sh); cash runway through Feb 2024

## Summary
- Net loss of $3.6M ($0.02 EPS) improved from $9.2M ($0.06 EPS) in Q1 2022.
- Cash and equivalents $36.9M; runway expected to fund operations through Feb 2024.
- I/ONTAK BLA under FDA review with PDUFA target date July 28, 2023.
- Mino-Lok Phase 3 trial expanding; enrollment uptick in U.S. and India.
- Director Dennis McGrath elected, replacing Dr. William Kane.

## SEC filing metadata
- accession: 0001213900-23-010323
- form_type: 8-K
- ticker: CTXR
- cik: 0001506251
- company_name: Citius Pharmaceuticals, Inc.
- filed_at: 2023-02-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506251/000121390023010323/0001213900-23-010323-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506251/000121390023010323/ea173123-8k_citiuspharma.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-010323
- JSON: https://secwatch.observer/filing/0001213900-23-010323.json
- Plain text: https://secwatch.observer/filing/0001213900-23-010323.txt

## Key facts
- Earnings Releases
  Citius Pharmaceuticals, Inc. reported the fiscal first quarter ended December 31, 2022 results: net income Net loss was $3.6 million, or ($0.02) per share, EPS $0.02.
  - Period: the fiscal first quarter ended December 31, 2022
  - Net income: Net loss was $3.6 million, or ($0.02) per share
  - EPS: $0.02
  - Result: reported results
  source text: On February 10, 2023, we issued a press release announcing our results of operations for the first quarter of fiscal 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1506251/000121390023010323/0001213900-23-010323-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.